Loading search results
HEALTHS
HEALTHS - Holistic Evaluation of Approaches to Long-term Health and Survivorship (Focus Phytotherapy) A Single-center, Minimal-risk, Two-phase Study Including a Quantitative Observational Survey and an Interventional Mixed-methods Component With Focus Group Sessions.
Sponsor study identifier
interventional
500
1 country
1
Study Start
June 8, 2026
Actual (reported)Primary Completion
March 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study aims at investigating behaviors of cancer patient regarding complementary and alternative medicine (CAM) with mixed methodology. The investigators want to realize a pilot study evaluating patient's use and attitude with particular focus on natural products (phyto- and aromatherapy). They aim at giving an overview of their actual consumption (and not to promote natural products) in order to (1) prioritize needs regarding integrative care to promote quality of life and survivorship; (2) identify potential short- or medium-term safety issues for patients; and (3) propose adequate pharmaceutical council. Studied period (years): 2026, approximately 9 months
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 8, 2026
Actual (reported)June 29, 2026
Actual (reported)August 4, 2026
Actual (reported)March 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Percentage of Participants Reporting Use of Complementary and Alternative Medicine as Assessed by the HEALTHS Quantitative Questionnaire
The percentage of participants who report currently or previously using at least one complementary and alternative medicine (CAM) approach will be calculated from responses to the study-specific HEALTHS quantitative questionnaire. CAM includes complementary practices, natural health products, herbal products, dietary supplements, phytotherapy, aromatherapy, and other complementary approaches included in the questionnaire. The numerator will be the number of participants reporting use of at least one CAM approach. The denominator will be the number of participants who complete the relevant questionnaire item. Results may also be reported by CAM category, cancer type, cancer stage, treatment type, time since diagnosis, province of residence, and self-reported sociodemographic characteristics.
At completion of the Phase 1 quantitative questionnaire, administered once during the 3-month survey recruitment period The protocol specifies that the Phase 1 questionnaire records CAM use, motivations, perceived benefits and risks, information sources
Percentage of Participants Reporting Unmet Needs for Information or Professional Guidance About Complementary and Alternative Medicine as Assessed by the HEALTHS Quantitative Questionnaire
Phase 1 - quantitative survey : Minimum 500 patients. A survey will be completed by cancer patients over a three-month period to assess their use of complementary and alternative medicine (CAM). A survey will be made available to cancer patients over a three-month period to assess their use of complementary and alternative medicine (CAM). The questionnaire will be accessible through non-intrusive methods, including dissemination via healthcare professionals, display of study information and QR codes on hospital screens or in waiting areas, and access via a secure online link (REDCap). The survey will be available in both paper format and online via QR code (REDCap). The paper versions of the survey will be collected in a dedicated box at the entrance of the Bordet building. The questionnaire is fully anonymous, and no directly identifiable personal data will be collected.
Phase 2 - Interventional mixed-methods evaluation of cancer patient's behaviour regarding CAMs : patients (men and women) after acute phase of anti-cancer treatment. This study will include a total of 6 to 8 focus groups, with each group consisting of 5 to 10 participants. So, in total, we expect 30 to 60 participants. Participants in this arm will take part in semi-structured focus group sessions exploring their knowledge, use, motivations, perceived benefits and risks, sources of information, and expectations regarding CAM in cancer care and survivorship. Before and after the session, participants will complete anonymous questionnaires. Focus groups will last approximately two hours, include up to eight participants, and may use interactive tools to facilitate discussion. Sessions will be audio-recorded with consent, transcribed verbatim, and analyzed using rapid qualitative methods. A structured medication review based on self-reported treat
Before each focus group session, participants will complete an anonymous pre-session questionnaire, including province of residence, to explore potential regional differences in access to CAM resources, healthcare services, and information. Each session will start with a standardized introduction and presentation of the study framework, including the scope and limits of the discussion. Participants will then be invited to share their experiences in a semi-structured group discussion guided by an interview guide developed by the research team. Topics will include knowledge and use CAM, motivations and perceived benefits, perceived risks, concerns and barriers, sources of information, and needs and expectations regarding integrative care and survivorship. Interactive techniques, such as visual supports or mapping exercises, may be used to facilitate discussion. Sessions will be audio-recorded with consent, transcribed verbatim, and analyzed using rapid qualitative methods.
Institut Jules Bordet
Brussels, 1070, Belgium
Echterbille MA, Horicks F, Dhont J, De Wilde V. Implementing an integrative oncology pathway in a comprehensive cancer center: expert insights and perspectives. Curr Opin Oncol. 2025 Jul 1;37(4):283-289. doi: 10.1097/CCO.0000000000001150. Epub 2025 Apr 23.
Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013 Sep 18;13:117. doi: 10.1186/1471-2288-13-117.
Florence Souard, PhD
Université Libre de Bruxelles
Laura Polastro, MD
Jules Bordet Institute
First Submitted
June 29, 2026
First Posted
August 4, 2026
The percentage of participants reporting at least one unmet need related to information, counseling, or professional guidance about complementary and alternative medicine will be calculated using the study-specific HEALTHS quantitative questionnaire. Unmet needs may include insufficient access to reliable CAM information, uncertainty regarding the benefits or risks of CAM, uncertainty regarding interactions with conventional cancer treatments, difficulty identifying qualified professionals, or a desire to discuss CAM with an oncology healthcare professional. The numerator will be the number of participants reporting at least one unmet information or guidance need. The denominator will be the number of participants completing the relevant questionnaire items. Individual unmet-need categories and sources of CAM information will also be summarized as numbers and percentages.
At completion of the Phase 1 quantitative questionnaire, administered once during the 3-month survey recruitment period The protocol identifies CAM information and guidance needs as a primary endpoint and states that quantitative information on unmet ne
Percentage of Participants Reporting Adherence to Prescribed Long-Term Oral Anticancer Therapy as Assessed by the HEALTHS Pre-Focus Group Questionnaire
Among Phase 2 participants receiving long-term oral anticancer therapy, the percentage who report taking their prescribed anticancer treatment in accordance with the prescribed dose and schedule will be summarized using the study-specific HEALTHS pre-focus group questionnaire. The numerator will be the number of eligible participants reporting adherence to their prescribed oral anticancer therapy. The denominator will be the number of Phase 2 participants receiving long-term oral anticancer therapy who complete the relevant adherence item or items. Reported reasons for missed, reduced, delayed, interrupted, or discontinued doses, including reasons associated with CAM use or management of treatment-related symptoms, will be summarized descriptively where collected.
Immediately before the participant's focus group session The protocol lists treatment adherence alongside conventional oral therapy as a primary endpoint. However, it does not identify a validated adherence scale or provide a scoring method.
Distribution of Complementary and Alternative Medicine Approaches and Uses as Assessed by the HEALTHS Quantitative Questionnaire
At completion of the Phase 1 quantitative questionnaire, administered once during the 3-month survey recruitment period
Number of Complementary and Alternative Medicine Approaches Used per Participant as Assessed by the HEALTHS Quantitative Questionnaire
At completion of the Phase 1 quantitative questionnaire, administered once during the 3-month survey recruitment period This needs to remain separate from the percentage of CAM users because its unit is a count of CAM approaches per participant, rather
Percentage of Participants Reporting Each Motivation for Complementary and Alternative Medicine Use as Assessed by the HEALTHS Quantitative Questionnaire
At completion of the Phase 1 quantitative questionnaire, administered once during the 3-month survey recruitment period
Percentage of Participants Reporting Each Source of Information About Complementary and Alternative Medicine as Assessed by the HEALTHS Quantitative Questionnaire
At completion of the Phase 1 quantitative questionnaire, administered once during the 3-month survey recruitment period
Percentage of Participants Reporting Perceived Benefits From Complementary and Alternative Medicine as Assessed by the HEALTHS Quantitative Questionnaire
At completion of the Phase 1 quantitative questionnaire, administered once during the 3-month survey recruitment period
Exploratory and Operational Objectives
3 months
A fully anonymous survey will be distributed to cancer patients over three months to assess their use of complementary and alternative medicine (CAM). The questionnaire will be available on paper and online via a secure REDCap link or QR code, disseminated through healthcare professionals and non-intrusive hospital channels, including screens and waiting areas. Paper questionnaires will be collected in a dedicated box at the Bordet building entrance. The survey will collect self-reported data on medical history, treatments, symptoms, CAM use, motivations, perceived benefits and risks, information sources, and interest in integrative care programs. Basic sociodemographic data, province of residence, and optional self-identified ethnocultural background will be collected to explore differences in CAM use, access to information, and patient needs by geographic and sociocultural context. No directly identifiable data will be collected, and results will be analyzed in aggregated form.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Averill JB. Matrix analysis as a complementary analytic strategy in qualitative inquiry. Qual Health Res. 2002 Jul;12(6):855-66. doi: 10.1177/104973230201200611.
Lohr AM, Griffin JM, Raygoza JP, Frick MR, Minteer SA, Tilburt JC, Cheville AL, Austin JD. The role of community health workers in a collaborative care management intervention for cancer pain management: a feasibility study for a randomized controlled trial. Ann Palliat Med. 2025 Jan;14(1):13-28. doi: 10.21037/apm-24-125.
Lewinski AA, Crowley MJ, Miller C, Bosworth HB, Jackson GL, Steinhauser K, White-Clark C, McCant F, Zullig LL. Applied Rapid Qualitative Analysis to Develop a Contextually Appropriate Intervention and Increase the Likelihood of Uptake. Med Care. 2021 Jun 1;59(Suppl 3):S242-S251. doi: 10.1097/MLR.0000000000001553.
Taylor B, Henshall C, Kenyon S, Litchfield I, Greenfield S. Can rapid approaches to qualitative analysis deliver timely, valid findings to clinical leaders? A mixed methods study comparing rapid and thematic analysis. BMJ Open. 2018 Oct 8;8(10):e019993. doi: 10.1136/bmjopen-2017-019993.
Gale RC, Wu J, Erhardt T, Bounthavong M, Reardon CM, Damschroder LJ, Midboe AM. Comparison of rapid vs in-depth qualitative analytic methods from a process evaluation of academic detailing in the Veterans Health Administration. Implement Sci. 2019 Feb 1;14(1):11. doi: 10.1186/s13012-019-0853-y.
Corvaisier M, Duval O, Paillassa J, Hunault-Berger M, Spiesser-Robelet L. [Implementation of pharmaceutical consultations in oncohematology in a teaching hospital: Over one year outcomes]. Ann Pharm Fr. 2023 Jun;81(4):710-719. doi: 10.1016/j.pharma.2022.12.001. Epub 2022 Dec 10. French.
Wiens MO, Grunau BE. Exposure to Alternative Healthcare Providers and Adherence to Guidelines among Patients with Diabetes. Can J Diabetes. 2011 Dec;35(5):512-7. doi: 10.1016/S1499-2671(11)80007-9.
Sont OM, Rombouts MD, Crul M. Attitude of healthcare professionals toward the use of complementary and alternative medication during anti-cancer therapy. J Oncol Pharm Pract. 2024 Jun;30(4):628-635. doi: 10.1177/10781552231179899. Epub 2023 May 31.
Schils A, Lechon AS, Rondeaux S, Souard F, Van Laethem JL, Pochet S, Mathieu V, De Vriese C. Cancer patients' behaviors and attitudes toward natural health products. BMC Complement Med Ther. 2023 Dec 6;23(1):442. doi: 10.1186/s12906-023-04278-0.
Wu A, Wu Y, Natarajan V, Singh P, Cheema W, Hossain R, Liu C, Mejia Y, Oo MHH, Valenzano B, Xu Y. Complementary and Alternative Medicine Use in Patients With Cancer and Immigration Background. JCO Glob Oncol. 2023 Jun;9:e2200303. doi: 10.1200/GO.22.00303.
Kallman M, Bergstrom S, Carlsson T, Jaras J, Holgersson G, Nordberg JH, Nilsson J, Wode K, Bergqvist M. Use of CAM among cancer patients : Results of a regional survey in Sweden. BMC Complement Med Ther. 2023 Feb 16;23(1):51. doi: 10.1186/s12906-023-03876-2.
Study Start
June 8, 2026
Actual (reported)Primary Completion
March 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 4, 2026
Record last verified: 2026-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: